Empagliflozin: Role in Treatment Options for Patients with Type 2 Diabetes Mellitus

Empagliflozin is an oral treatment for type 2 diabetes mellitus (T2DM), one of the leading causes of death in the US and around the world. Recently, the EMPA-REG OUTCOME study has shown that empagliflozin added to standard of care treatment reduced the risk of cardiovascular (CV) events in patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Anderson, John E., Wright, Eugene E., Shaefer, Charles F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5306110/
https://www.ncbi.nlm.nih.gov/pubmed/27837465
http://dx.doi.org/10.1007/s13300-016-0211-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5306110/
https://www.ncbi.nlm.nih.gov/pubmed/27837465
http://dx.doi.org/10.1007/s13300-016-0211-x

Ejemplares similares